17/01/2024 07:30
Informations privilégiées / Autres communiqués
Télécharger le fichier original

INFORMATION REGLEMENTEE

Commercial launch of BIOCERA-VET® in Germany

13 BIOCERA-VET® references now available in Germany, the largest companion
animal health market in Europe
Attendance to Leipzig Veterinary Congress, the biggest event of the country
Presentation of the BIOCERA-VET® range at two open lectures

Gosselies (Wallonia, Belgium), January 17, 2024 – 7.30 am CET – TheraVet (ISIN:
BE0974387194 – ticker: ALVET), a pioneering company in the management of osteoarticular
diseases in pets, announces today the commercial launch of its BIOCERA-VET® products in
Germany.

With a total pet population of 27 million (of which 10.3 million dogs and 16.7 million cats) and a
pet ownership of 47%1, Germany is the dominating companion animal market in Europe. Driven
by the growing number of mixed-breed dogs in Germany, demand for animal health products and
services is expected to increase significantly, with an estimated average annual growth rate of
4.5% over the next 6 years (2024-2029) 2.

To support this launch, the Company is attending the Leipzig Veterinary Congress, the biggest
event for veterinary medicine in the German-speaking area, taking place in Leipzig from January
18th to 20th. The last edition gathered 5,600 attendees coming from Germany and abroad. The
Company assists to this event along with AWEX (Wallonia Export & Investment Agency) in the
context of a mission dedicated to the Animal Health.

The Company will also have the chance to present the product line during 2 open lectures: first,
on January 18th dedicated to on BIOCERA-VET® OSTEOSARCOMA, a new solution in limb-sparing
management in canine osteosarcoma and, a second on January 19th on BIOCERA-VET® BONE
SURGERY line.

The BIOCERA-VET® full range is now available via our webshop www.bioceravet.com.


About TheraVet SA
TheraVet is a veterinary biotechnology company specializing in osteoarticular treatments for companion
animals. The Company develops targeted, safe and effective treatments to improve the quality of life of pets
suffering from joint and bone diseases. For pet owners, the health of their pets is a major concern and
TheraVet’s mission is to address the need for innovative and curative treatments. TheraVet works closely
with international opinion leaders in order to provide a more effective response to ever-growing needs in


1 Der Deutsche Heimtiermarkt, 2021
2 https://www.mordorintelligence.com/industry-reports/germany-veterinary-healthcare-market-
industry/market-size

1
the field of veterinary medicine. TheraVet is listed on Euronext Growth ® Paris and Brussels, has its head
office in Belgium (Gosselies) with a US subsidiary.
For more information, visit the TheraVet website or follow us on LinkedIn / Facebook / Twitter

About BIOCERA-VET®
In close collaboration with an international scientific board, THERAVET ® has developed a new line of
calcium-phosphate and biological bone substitutes, BIOCERA-VET®. BIOCERA-VET® is a full range of
innovative, easy-to-use, efficient & cost-effective bone substitutes indicated in bone surgeries where a bone
graft is required and as a palliative alternative in the management of canine osteosarcoma. Based on
extremely promising clinical results, this line offers the possibility of a better, more convenient and more
efficient orthopedic surgery.
BIOCERA-VET® is declined in different lines:
➢ BIOCERA-VET® BONE SURGERY RTU, a ready-to-use highly injectable self-hardening calcium-
phosphate cement
➢ BIOCERA-VET® SMARTGRAFT, a naturally osteoconductive bone graft
➢ BIOCERA-VET® GRANULES, an affordable biocompatible calcium-phosphate bone substitute
➢ BIOCERA-VET® OSTEOSARCOMA RTU, a ready-to-use highly injectable calcium-phosphate bone
substitute for cementoplasty
➢ BIOCERA-VET® COMBO-CLEAN, a local and long-lasting antibiotic delivery calcium-phosphate bone
substitute

For more information, visit BIOCERA-VET website.

Contacts

TheraVet NewCap NewCap Belgique
Chief Operating Officer Investor Relations and Press Relations
Sabrina Ena Financial Communications Laure-Eve Monfort
investors@thera.vet Théo Martin / Nicolas Fossiez lemonfort@newcap.fr
Tel: +32 (0) 71 96 00 43 theravet@newcap.eu Tel: + 32 (0) 489 57 76 52
Tel: +33 (0)1 44 71 94 94

Press Relations
Arthur Rouillé
theravet@newcap.eu
Tel: +33 (0)1 44 71 00 15




2